Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Completed1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (33.3%)
N/A2 (66.7%)

Trials by Status

completed133%
not_yet_recruiting133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

NCT07118592
completednot_applicable

CARDIA-Salt Sensitivity of Blood Pressure (SSBP)

NCT04258332
recruitingphase_4

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

NCT06983054

Clinical Trials (3)

Showing 3 of 3 trials
NCT07118592Not Applicable

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

Not Yet Recruiting
NCT04258332Not Applicable

CARDIA-Salt Sensitivity of Blood Pressure (SSBP)

Completed
NCT06983054Phase 4

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
3